FDA’s proposal that the indication statement for accelerated approval drugs reflect the conditions for “continued approval” has drawn objections from two biopharmaceutical industry groups.
In May 27 comments on a recent FDA draft guidance, the Pharmaceutical Research and Manufacturers of America says such a statement is not the type of scientific information that a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?